Sunderland based Arquer Diagnostics Ltd , a diagnostic company which has developed a
high sensitivity, high specificity, ELISA-based urine test for cancer, announced that it has appointed Nadia Whittley as CEO. With significant experience in strategy, sales and marketing, organisational effectiveness, M&A and fundraising in the small and mid-cap sectors, Nadia’s focus at Arquer will be to execute the commercial launch of the Company’s MCM5-ELISA diagnostic test, and expansion of the technology into a wider range of cancers.
With over 25 years’ experience in the life science sector, Nadia Whittley has an outstanding leadership record of growing revenues and motivating teams spanning several therapeutic areas and across different geographies, including EMEA, Asia Pacific and North America. Most recently Nadia was Partner and Managing Director, Europe, of Tefen Management Consulting, where she was responsible for the design and implementation of a 5-year strategic plan and development of the Life Science Business Unit in EMEA. Previously Nadia was CEO at Alium Medical Ltd, Managing Director Medical Devices EAME at Allergan Inc., Marketing Director EMEA in Interventional Cardiology at Boston Scientific International, and a non-executive Board member at Peptonic Medical AB.
Commenting on the appointment, Dr Sandy Primrose, Chairman Arquer, said: “I would like to welcome Nadia and am delighted that we have someone with her commercial background as our new CEO. Her experience of successfully launching new technologies across multiple regions and her knowledge of the sector make her a real asset to the business, particularly as we move forward to commercialise our MCM5-ELISA diagnostic test. I would also like to take this opportunity to thank outgoing CEO, Dr Ian Campbell, for his work in the development of Arquer to this exiting stage and to wish him well in his new role.”
Nadia Whittley commented: “In Arquer, and the introduction of the company’s MCM5-ELISA diagnostic test, I see a real opportunity to provide a novel technology that will both improve patient outcomes and help to reduce healthcare costs. The MCM5-ELISA is expected to significantly reduce the number of patients undergoing invasive and costly techniques such as cystoscopy and biopsy, because it offers highly accurate diagnostic results from small amounts of body fluid. I am delighted to have joined Arquer at such an exciting time for the company.”
Arquer’s diagnostic test, the MCM5-ELISA, detects the presence of minichromosome maintenance (MCM) protein, a marker for the presence of dividing cancer cells, in urine, to accurately diagnose both bladder and prostate cancer. MCM proteins are excellent biomarkers, being directly involved in cell replication, and are shed into urine by both prostate and bladder tumours.